These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 17146166)

  • 41. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.
    Baselga J; Tripathy D; Mendelsohn J; Baughman S; Benz CC; Dantis L; Sklarin NT; Seidman AD; Hudis CA; Moore J; Rosen PP; Twaddell T; Henderson IC; Norton L
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):78-83. PubMed ID: 10482197
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
    Goldenberg MM
    Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sentinel lymph node biopsy in patients with operable breast cancer treated with neoadjuvant chemotherapy.
    Rebollo-Aguirre AC; Gallego-Peinado M; Menjón-Beltrán S; García-García J; Pastor-Pons E; Chamorro-Santos CE; Ramos-Font C; Salamanca-Ballesteros A; Llamas-Elvira JM; Olea-Serrano N
    Rev Esp Med Nucl Imagen Mol; 2012; 31(3):117-23. PubMed ID: 21676504
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HER-2/neu expression in primary and metastatic breast cancer.
    Lower EE; Glass E; Blau R; Harman S
    Breast Cancer Res Treat; 2009 Jan; 113(2):301-6. PubMed ID: 18273700
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Status of HER2 amplification, polysomy 17 and histopathological features of 425 Pakistani breast cancer patients.
    Moatter T; Aban M; Iqbal W; Azam I; Pervaiz A; Siddiqui F; Murad F; Pervez S
    Asian Pac J Cancer Prev; 2011; 12(11):3069-73. PubMed ID: 22393991
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.
    Seidman AD; Fornier MN; Esteva FJ; Tan L; Kaptain S; Bach A; Panageas KS; Arroyo C; Valero V; Currie V; Gilewski T; Theodoulou M; Moynahan ME; Moasser M; Sklarin N; Dickler M; D'Andrea G; Cristofanilli M; Rivera E; Hortobagyi GN; Norton L; Hudis CA
    J Clin Oncol; 2001 May; 19(10):2587-95. PubMed ID: 11352950
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer.
    Wilks S; Puhalla S; O'Shaughnessy J; Schwartzberg L; Berrak E; Song J; Cox D; Vahdat L
    Clin Breast Cancer; 2014 Dec; 14(6):405-12. PubMed ID: 25024001
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Successful neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for an elderly patient with inflammatory breast cancer.
    Shimizu T; Hirano A; Watanabe O; Kinoshita J; Kimura K; Kamimura M; Domoto K; Kim N; Ogawa K; Fujibayashi M
    Anticancer Res; 2010 Feb; 30(2):581-5. PubMed ID: 20332474
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [A Case of Luminal-HER2 Advanced Breast Cancer with Liver Metastasis Showed Pathological Complete Response to the Therapy with Pertuzumab plus Trastuzumab plus Docetaxel].
    Hamaoka A; Matsuda T; Konishi E; Taguchi T
    Gan To Kagaku Ryoho; 2016 Sep; 43(9):1097-100. PubMed ID: 27628551
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Preoperative therapy with trastuzumab and paclitaxel in a stage IV advanced breast cancer with complete pathologic response].
    Rai Y; Sagara Y; Sagara Y; Takahama T; Matsuyama Y; Ando M; Sagara Y; Ooi Y; Inoue K; Kurosumi M
    Gan To Kagaku Ryoho; 2007 Jan; 34(1):65-8. PubMed ID: 17220672
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
    Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
    Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacology and therapeutic use of trastuzumab in breast cancer.
    Treish I; Schwartz R; Lindley C
    Am J Health Syst Pharm; 2000 Nov; 57(22):2063-76; quiz 2077-9. PubMed ID: 11098307
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Trastuzumab use for metastatic breast cancer in pregnancy.
    Sekar R; Stone PR
    Obstet Gynecol; 2007 Aug; 110(2 Pt 2):507-10. PubMed ID: 17666645
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antemortem diagnosis of pulmonary tumor thrombotic microangiopathy in a patient with recurrent breast cancer: a case report.
    Takahashi Y; Uruga H; Fujii T; Mochizuki S; Hanada S; Takaya H; Miyamoto A; Morokawa N; Kurosaki A; Kishi K
    BMC Cancer; 2016 Aug; 16(1):666. PubMed ID: 27549622
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Level of HER2/neu amplification in primary tumours and metastases in HER2-positive breast cancer and survival after trastuzumab therapy.
    Gullo G; Bettio D; Zuradelli M; Masci G; Giordano L; Bareggi C; Tomirotti M; Salvini P; Runza L; La Verde N; Santoro A
    Breast; 2013 Apr; 22(2):190-193. PubMed ID: 23473771
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Successful ventilator weaning by trastuzumab in a HER2-positive breast cancer patient with multiple lung metastases].
    Matsuda T; Fujita H; Kunimoto Y; Hosono M; Kimura T; Hayashi T; Maeda T; Yamakawa J; Maeda N; Mizumoto T; Maruyama S; Uenaka Y; Ogino K
    Gan To Kagaku Ryoho; 2013 Jun; 40(6):773-6. PubMed ID: 23863656
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HER2-positive breast cancer brain metastases: multiple responses to systemic chemotherapy and trastuzumab--a case report.
    Church DN; Bahl A; Jones A; Price CG
    J Neurooncol; 2006 Sep; 79(3):289-92. PubMed ID: 16821088
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer.
    Di Palma S; Collins N; Faulkes C; Ping B; Ferns G; Haagsma B; Layer G; Kissin MW; Cook MG
    J Clin Pathol; 2007 Sep; 60(9):1067-8. PubMed ID: 17293390
    [No Abstract]   [Full Text] [Related]  

  • 59. Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival.
    Nishimura R; Okumura Y; Arima N
    Breast Cancer; 2008; 15(1):57-64. PubMed ID: 18224396
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prevalence and management of HER2/neu-positive early breast cancer in a single institution following availability of adjuvant trastuzumab.
    Chan A; McGregor SR
    Intern Med J; 2012 Mar; 42(3):267-74. PubMed ID: 21241440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.